Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

Interest Coverage 9.15
HSP's Interest Coverage is ranked lower than
73% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.57 vs. HSP: 9.15 )
Ranked among companies with meaningful Interest Coverage only.
HSP' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.15
Current: 9.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

» HSP's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
Q1 2015

HSP Guru Trades in Q1 2015

Jeremy Grantham 657,484 sh (New)
Mario Gabelli 834,303 sh (+136.77%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers Sold Out
Vanguard Health Care Fund Sold Out
Jeff Auxier 119,147 sh (-6.11%)
Paul Tudor Jones 5,652 sh (-71.45%)
Jim Simons 93,800 sh (-85.15%)
» More
Q2 2015

HSP Guru Trades in Q2 2015

George Soros 172,139 sh (New)
Paul Tudor Jones 318,431 sh (+5533.95%)
Jim Simons 307,400 sh (+227.72%)
Jeremy Grantham 1,144,500 sh (+74.07%)
Mario Gabelli 1,018,420 sh (+22.07%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 118,472 sh (-0.57%)
» More
Q3 2015

HSP Guru Trades in Q3 2015

Jim Simons Sold Out
George Soros Sold Out
Robert Bruce Sold Out
Michael Price Sold Out
Jeremy Grantham Sold Out
Jeff Auxier Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Traded in other countries:HOS.Germany,

Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.

Guru Investment Theses on Hospira Inc

Mario Gabelli Comments on Hospira Inc. - Oct 19, 2015

Hospira Inc. (NYSE:HSP), based in Lake Forest, Illinois, is the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. On February 5, 2015, the company received a $90 per share cash merger offer from Pfizer Inc., valuing Hospira at $15.2 billion. The transaction closed on September 3, 2015, following shareholder and regulatory approvals, and the deal created a leading global injectables business. The Fund earned an annualized return of 5.82%.

From Mario Gabelli (Trades, Portfolio)'s ABC Fund third quarter commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Hospira Inc

Pfizer Investors Mood Dampened by Second Quarter Earnings Company’s guidance holds steady, but established drugs disappointed, pulling the stock downwards
Pharma major Pfizer (NYSE:PFE) raised its earnings guidance for 2016 after the first quarter results, increasing their 2016 revenue expectation to be in the range of $51 billion to $53 billion - a full two billion higher than their previous projection of $49 billion to $51 billion. After terminating its plan for a $150 billion mega-merger with Allergan (NYSE:AGN) earlier this year, Pfizer reported 11% revenue growth for the second quarter and 15% growth during the first half of this year compared to last year. These would seem to be solid numbers, but the stocks tell us a different story. Read more...
Michael Price Sells Holding in Hospira Guru adds to stakes in Dolby Laboratories and United States Steel
Michael Price (Trades, Portfolio) is known to prefer out-of-favor small cap companies that offer good value when he makes his investment decisions, and many of his third-quarter transactions fit that description, but some of his largest transactions involved companies with caps that exceeded several billion dollars. Read more...



Buy Back

Yield on cost (5-Year) 0.40
HSP's Yield on cost (5-Year) is ranked lower than
88% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. HSP: 0.40 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
HSP' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.4

Valuation & Return


More Statistics

Revenue (TTM) (Mil) $4,636
EPS (TTM) $ 2.38
Short Percentage of Float1.03%
52-Week Range $46.56 - 90.63
Shares Outstanding (Mil)172.93

Analyst Estimate

Dec15 Dec16
Revenue (Mil $) 4,638 5,018
EPS ($) 2.54 3.22
EPS w/o NRI ($) 2.54 3.22
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for HSP


Articles On GuruFocus.com
Pfizer Refuses to Go the Spinoff Route Oct 17 2016 
Pfizer: Hospira Is Future; Xtandi Is Today’s Meal Sep 19 2016 
Pfizer Investors Mood Dampened by Second Quarter Earnings Aug 02 2016 
Michael Price Sells Holding in Hospira Dec 04 2015 
Auxier Buys New Stake in Allstate Nov 13 2015 
Sells and Additions in Third Quarter Have Greatest Impact on Mario Gabelli's Portfolio Oct 25 2015 
Mario Gabelli Comments on Hospira Inc. Oct 19 2015 
The Gabelli ABC Merger and Arbitrage Fund Q3 Shareholder Commentary Oct 19 2015 
Pfizer Nears Completion of Hospira Acquisition Aug 26 2015 
Weekly 52-Week Highs Highlight: Tim Hortons, Hospira, Kinder Morgan, Sigma-Aldrich Aug 25 2015 

More From Other Websites
Four Key Deals: Analyzing Pfizer’s Impending Growth Oct 14 2016
[$$] ICU Medical To Buy Pfizer Unit in $1 Billion Deal Oct 06 2016
ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For $1 Billion In... Oct 06 2016
Pfizer Investors Mood Dampened by Second Quarter Earnings Aug 02 2016
Pfizer earnings rise, boosted by Hospira assets May 03 2016
Hospira President, David J. Endicott, Joins ZELTIQ Aesthetics Board of Directors Apr 26 2016
Pfizer earnings fall on strong dollar, higher expenses Feb 02 2016
Novartis profits jump 73% on asset sales Jan 27 2016
Pfizer, Allergan weigh blockbuster merger: reports Oct 29 2015
India-based company doesn't want drug used for executions Sep 22 2015
APNewsBreak: Arkansas execution plan may use UK firm's drug Sep 18 2015
Ahead of the Bell: Activision Blizzard, United join S&P 500 Aug 28 2015
Pfizer Gets Approval For Hospira Acquisition Aug 24 2015
EU regulators clear Pfizer's purchase of Hospira Aug 04 2015
Citing hacking risk, FDA says Hospira pump shouldn't be used Jul 31 2015
FDA says hospitals should stop using Hospira pump Jul 31 2015
FDA says hospitals should stop using Hospira pump Jul 31 2015
FDA warns of security flaw in Hospira infusion pumps Jul 31 2015
Hospira beats 2Q profit forecasts Jul 29 2015
Appeals Court Makes Medicines Company Angiomax Loss Even Worse Jul 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)